Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: NUMIF )

0.1580 -0.0092 (-5.50%)
Streaming Delayed Price Updated: 3:29 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 161,181
Open 0.1580
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1672
Today's Range 0.1510 - 0.1700
52wk Range 0.1051 - 0.3113
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud 
Via Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga

Performance

YTD
+2.27%
+2.27%
1 Month
+22.48%
+22.48%
3 Month
+8.59%
+8.59%
6 Month
+0.77%
+0.77%
1 Year
-45.06%
-45.06%

More News

Read More
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Via Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Via Benzinga
Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Via Benzinga
Numinus Q2 2023: 581% Revenue Growth, 820% In Gross Profit And Strong Cash Position
Via Benzinga
EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
Via Benzinga
Check Out The Canadian Company Building On Several Vertical Psychedelics Businesses
Via Benzinga
Psychedelic Stock Gainers And Losers From April 11, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 6, 2023
Via Benzinga
This Psychiatrist Calls Cannabis Is A Minor-League Psychedelic & Undervalued Investment Opportunity
Via Benzinga
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Want To Become A Psychedelic-Assisted Therapist? This Company Offers A 'Pathway' Course
Via Benzinga
In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend?
Via Benzinga
EXCLUSIVE: Bienstar Wellness Expands Ibogaine Treatment For Addiction To Curitiba, 3rd Brazilian City Covered By The Co.
Via Benzinga
Psychedelic Stock Gainers And Losers From March 9, 2023
Via Benzinga
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Will Canada Follow Australia And Approve Psychedelic Assisted Therapy? This CEO Believes It Will
Via Benzinga
Psychedelic Stock Gainers And Losers From March 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.